JPMorgan Chase & Co. Buys 12,051 Shares of Iradimed Corporation (NASDAQ:IRMD)

JPMorgan Chase & Co. boosted its stake in Iradimed Corporation (NASDAQ:IRMD) by 70.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,226 shares of the medical equipment provider’s stock after acquiring an additional 12,051 shares during the quarter. JPMorgan Chase & Co. owned 0.23% of Iradimed worth $1,470,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Huntington National Bank lifted its position in Iradimed by 51.3% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after acquiring an additional 504 shares in the last quarter. Gladius Capital Management LP lifted its position in Iradimed by 126.6% during the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 965 shares in the last quarter. Quantbot Technologies LP lifted its position in Iradimed by 83.0% during the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 1,052 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Iradimed during the 3rd quarter worth about $126,000. Finally, SG Americas Securities LLC bought a new stake in Iradimed during the 3rd quarter worth about $147,000. 92.34% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO John Glenn sold 2,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 37.10% of the company’s stock.

Iradimed Price Performance

Shares of NASDAQ:IRMD opened at $60.34 on Friday. The company’s 50-day moving average price is $54.94 and its two-hundred day moving average price is $50.50. Iradimed Corporation has a one year low of $40.18 and a one year high of $61.00. The stock has a market capitalization of $764.51 million, a PE ratio of 41.33 and a beta of 0.81.

Iradimed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were given a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 0.99%. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.